1Spinale FG. Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardiovasc Res 2000,46(2) :225-238.
2Spinals FG. Matrix metallproteinases:regulation and dysregulation in the falling heart. Circ Res,2002,90(5) :520-530.
3Siwik DA, Chang DL, Colucci WS. Interleukin - 1 beta and tumor necrosis factor - alpha decrease collagen syntheis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res,2000,86( 12 ) :1259-1265.
4Spinale FG, Coker ML, Heung LJ, et al. A matrixmetallo-proteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000,102(16) :1944-1949.
5King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure:effects on left ventricular function and structure. Circ Res,2003,92 (2) :177-185.
6Dixon IM, Ju H, Reid WL, et al. Cardiac collagen remodeling in the cardlomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol, 1979,29 (7) : 1837 -1850.
7Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted over expression of tumor necrosis factor. Circulation2001,104(7 ) :826-831.
8McElmurray JH 3rd, Mukherjee R, New RB, et al. Angio-tension- converting enzyme and matrix metalloproteinase inhibition with developing heart failure:comparative effects of left ventricular function and geometry. J Pharmacol Exp Ther, 1999,29 (2) :799-811.
7Hijova E. Matrix metalloproteinases: Their biological functions and clinical implications[J ]. Bratisl Lek Listy,2005,106(3) : 127 - 132.
8Batlle M, Perez Villa F, Garcia Pras E, et al. Down - regulation of matrix metalloproteinase - 9 ( MMP - 9) expression in the mycvardium of congestive heart failure patients [ J ]. Transplant Proc, 2007,39 ( 7 ) : 2344 - 2346.
9Fdkin LE, Birks EJ, George R, et al. A quantitative gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the mycocardium of patients with deteriorating heart failure requiring left ventricular assist device support[J ]. J Heart Lung Transplant, 2006,25(12) : 1413 - 1419.
10Ahmed SH, Clark LL, Pennington WR, et al. Matrix metallopro teinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease[J]. Circulation, 2006,113 (17) : 2089-2096.
